Eli Lilly presented early clinical data supporting dose selection for brenipatide, its once-weekly dual GIP/GLP-1 receptor agonist being developed with a neuroscience and immunology rationale. At Psych Congress 2026, Lilly reported results from its Phase 1 J2S-MC-GZMD study (NCT06606106), focused on safety, pharmacokinetics, and pharmacodynamics. Lilly highlighted a mean half-life range between 9.08 and 12.5 days, with longer exposure seen at its highest tested dose. The program’s design aims to support durability beyond weekly dosing, while the development plan includes Phase 3 studies intended to evaluate brenipatide in major depressive disorder and alcohol use disorder. The presentation underscores Lilly’s continued push to translate its metabolic incretin platform into central nervous system and reward-related pathways, targeting conditions where GLP-1/GIP biology is still being tested clinically.